Ligand Pharmaceuticals Inc
XBER:LGDN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Ligand Pharmaceuticals Inc
XBER:LGDN
|
US |
|
U
|
USANA Health Sciences Inc
F:USJ
|
US |
|
P
|
Pilgrims Pride Corp
XBER:6PP
|
US |
|
S
|
Shake Shack Inc
SWB:9SH
|
US |
|
Mediobanca Banca di Credito Finanziario SpA
MIL:MB
|
IT |
|
N
|
Next PLC
F:NXG
|
UK |
Wall St Price Targets
LGDN Price Targets Summary
Ligand Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for LGDN is 145.06 EUR with a low forecast of 128.03 EUR and a high forecast of 177.83 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LGDN's stock price target?
Price Target
145.06
EUR
According to Wall Street analysts, the average 1-year price target for LGDN is 145.06 EUR with a low forecast of 128.03 EUR and a high forecast of 177.83 EUR.
What is the Revenue forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 14 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 16%.
What is the Gross Profit forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 18%. The projected CAGR for the next 7 years is 17%.
What is the Operating Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
34%
Over the last 14 years, the compound annual growth rate for Operating Income has been 26%. The projected CAGR for the next 8 years is 34%.
What is the Pre-Tax Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 24%.
What is the Net Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 7 years is 26%.
